U.S. Household Products Stock News

Earlier this month, Quanta Services reported a strong Q2 with its backlog rising about 50% year over year to US$53.40 billion, reflecting robust demand for AI-related energy infrastructure, electrification, and grid expansion projects. The company’s expanding backlog and upward earnings revisions, including expectations to more than double adjusted EPS by 2030, highlight how investors are focusing on Quanta’s role as a core contractor for the AI-driven power buildout and broader energy...

Hut 8 stock has delivered a 260.5% gain over the past year, yet its valuation checks still lean expensive, which raises questions about how much of the AI data center story is already reflected in the price. Over the last 12 months, Hut 8 is up 260.5%. This suggests very high expectations are already baked into the share price. The build out of Hut 8's AI focused data center pipeline and large contracted revenue backlog can support long term cash flows. At the same time, regulatory reviews...

Sempra (SRE) stock is reacting to fresh numbers after the company reported second quarter 2026 results, with higher net income and earnings per share, and adjusted its 2026 outlook while reaffirming 2027 guidance. See our latest analysis for Sempra. At a share price of US$85.94, Sempra has seen its short term share price performance soften, with a 30 day share price return down 6.84%. However, longer term total shareholder returns of 9.18% over one year and 52.43% over five years point to a...

ResMed stock has delivered a 36.4% gain over the past three years, yet the current share price still screens as cheap relative to an intrinsic value estimate from a Discounted Cash Flow (DCF) model and to market based multiples. Over the last three years ResMed has returned 36.4%, which puts recent weakness into context for anyone focused on longer holding periods. The latest pullback followed softer longer term revenue expectations linked to suspended ventilator sales and cost pressures...

Cushman & Wakefield recently reported second-quarter 2026 results, with sales rising to US$2,762.6 million while net income and earnings per share from continuing operations decreased compared with a year earlier. A few days later, the firm strengthened its Houston tenant representation team by hiring veteran broker Drew Morris as Executive Managing Director, adding nearly 30 years of commercial real estate experience and more than 11 million square feet of completed transactions to its...

Burlington Stores (BURL) is back in focus after announcing a planned change in its top human resources role, raising fresh questions about leadership continuity, culture and long term execution for the off price retailer. See our latest analysis for Burlington Stores. The leadership reshuffle comes after a mixed stretch for Burlington Stores, with the share price down 9.33% over the past week and 2.45% over the past month, yet still showing a 17.74% 90 day share price return and a 21.30% one...

Arrowhead Pharmaceuticals has already obtained European marketing authorisation for REDEMPLO (plozasiran) to help reduce triglyceride levels in adults with familial chylomicronaemia syndrome, based on positive Phase 3 PALISADE data showing significant median fasting triglyceride reductions versus placebo at the 25 mg dose. This approval marks Arrowhead’s transition from a pure development-stage RNAi player toward commercialisation in a rare disease with high unmet medical need and serious...

In August 2026, Genpact reported second-quarter 2026 results showing year-over-year growth in sales to US$1,343.44 million and higher net income of US$145.74 million, alongside updated guidance calling for continued revenue and earnings expansion through the third quarter and full year. At the same time, Genpact was named to TIME magazine's World's Most Sustainable Companies 2026 list for the second consecutive year, underlining how its financial performance is increasingly paired with...

Why Zacks Coverage Has Put Fresh Attention on VEON Recent Zacks coverage spotlighted VEON (VEON) for what it described as favorable valuation metrics and a strong earnings outlook. This recognition appears to be a key reason the stock is drawing more investor attention. See our latest analysis for VEON. Over the past month VEON has seen an 11.35% share price return to US$57.48, while its year to date share price return of 9.07% contrasts with a 1 year total shareholder return that is down...

Photronics has delivered a 151.9% total return over the past five years, yet its valuation checks send a mixed message at a time when the stock is under scrutiny following securities fraud class action filings in 2026. A 151.9% return over five years suggests Photronics has rewarded long term shareholders, which raises the question of how much of that success is already reflected in today's price. On one side, growth expectations for high end chip related demand can support interest in the...

Brink's stock has delivered a 57.6% return over the past three years, yet current valuation checks paint a mixed picture rather than a clear bargain or clear overvaluation. Over three years Brink's has returned 57.6%, which puts more focus on whether the current price already reflects much of that progress. Recent revenue growth and progress on acquisitions can support expectations for future cash flows, while slightly softer near term revenue expectations and a share price pullback since...

Uranium Energy (UEC) continues to draw attention after recent share price moves, with the stock last closing at $11.17 and company performance over the past month and past 3 months in focus for investors. See our latest analysis for Uranium Energy. Over the past month Uranium Energy has logged a 20.37% share price return, while its year to date share price return is down 14.8%. Longer term total shareholder returns over 3 and 5 years remain very large, which points to momentum that has...

Ormat Technologies (ORA) drew fresh attention after reporting second quarter 2026 results and updating its outlook. Investors now have new revenue figures, earnings metrics, and guidance to assess the stock’s current setup. See our latest analysis for Ormat Technologies. At a share price of US$113.91, Ormat Technologies has seen an 8.8% 1 month share price return but a 12.8% decline over 3 months, while its 1 year total shareholder return of 24.3% and 5 year total shareholder return of 73.6%...

NiSource (NI) has drawn fresh attention after its second quarter results showed lower adjusted earnings per share, while management reaffirmed long term targets and highlighted newly approved data center contracts with Amazon and Alphabet. See our latest analysis for NiSource. NiSource’s share price has softened in recent months, with a 30 day share price return of down 7.85% and a 90 day share price return of down 10.65%. At the same time, the 1 year total shareholder return of 4.30% and...

Cirrus Logic stock has delivered a 51.5% gain over the past three years, yet current checks suggest the shares may still trade below an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and earnings multiples that both point to undervaluation. Cirrus Logic has returned 51.5% over three years, which puts recent short term pullbacks into the context of a solid medium term gain. Record revenue supported by demand for custom components in smartphones can help underpin...

Geopolitics around the Strait of Hormuz, oil benchmarks like Brent and WTI pushing above key price levels, and higher long term U.S. yields are pulling energy stocks back into focus. That mix can quickly reshape cash flow expectations, debt costs and investor sentiment. This article explains how those forces relate to the Global Energy & Oil Producers screener and identifies 3 stocks that appear most exposed to the latest headlines. The three stocks highlighted below are just a starting...

CareTrust REIT (CTRE) drew investor attention after updating its 2026 net income guidance to approximately $1.53 to $1.56 per share and reporting higher second quarter and first half earnings on August 6, 2026. See our latest analysis for CareTrust REIT. CareTrust REIT's guidance update and solid first half figures come after a mixed stretch for the stock, with the share price down 8.44% over 30 days but still showing an 8.12% year to date share price return and a 1 year total shareholder...

Ascendis Pharma (NasdaqGS:ASND) reported new positive Phase 2 COACH Trial data for TransCon CNP and TransCon hGH combination therapy in children with achondroplasia, along with Week 104 results from the ApproaCH Trial. The company highlighted durable proportional growth effects and a favorable safety profile in the combination regimen based on these trial updates. Ascendis Pharma also completed enrollment in the pivotal reACHin Trial, marking a key step toward potential regulatory...

State Street (STT) has moved to refine its capital structure, filing amendments in Massachusetts to define its new Series L preferred stock after completing a $500 million offering of callable, non cumulative, perpetual depositary shares. See our latest analysis for State Street. The preferred offering and related amendments come at a time when State Street’s share price has moved firmly higher, with a 90 day share price return of 27.94% and a 1 year total shareholder return of 78.08%, which...

Recent commentary on Kohl's (KSS) is driven by ongoing weakness in same-store sales, compressed operating margins, and a high net debt to EBITDA ratio, which raises questions about financial flexibility and potential dilution risk. See our latest analysis for Kohl's. The recent 90 day share price return of 64.22% contrasts with a year to date share price decline of 9.65%. The 1 year total shareholder return of 45.74% sits against a 5 year total shareholder return decline of 54.78%, suggesting...

Abbott Laboratories stock has declined 13.3% over the past year, yet the current valuation checks send a mixed message, because the Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market based multiples suggest the share price is roughly in line with peers. Over the last 12 months the share price is down 13.3%, which invites a closer look at whether recent weakness already reflects the key risks in Abbott Laboratories. Recent product momentum around its...

Lightwave Logic, Inc. reported its second-quarter 2026 results, with sales of US$32,751 versus US$25,605 a year earlier and a wider net loss of US$6.61 million compared with US$4.97 million. While revenue in the quarter and year-to-date edged higher, the company’s net losses and loss per share continued to expand, sharpening investor focus on its path toward commercialization. We’ll now examine how Lightwave Logic’s widening net loss, despite incremental sales growth, shapes the company’s...

In recent days, Kupando Therapeutics announced a collaboration using Natera’s Latitude tissue-free MRD assay to monitor ctDNA dynamics in a Phase 1 trial of its KUP-101 immunotherapy across advanced skin cancers, while Natera also reported higher second-quarter 2026 revenue of US$752.75 million and a reduced net loss of US$66.97 million versus a year earlier. These developments, alongside Natera’s raised 2026 revenue guidance, PMDA submission for Signatera in muscle-invasive bladder cancer,...

ITT Inc. recently reported past second-quarter and six-month 2026 results, with sales rising to US$1,473.1 million and US$2,685.0 million respectively, while net income and earnings per share from continuing operations declined compared with the prior year. Alongside these mixed results, ITT raised its full-year 2026 earnings guidance to US$4.47–US$4.67 per share and affirmed its quarterly dividend of US$0.386, signaling management confidence despite acquisition-related pressure on...